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Abstract
Background—Angiotensin converting enzyme (ACE) inhibitors are known to improve clinical
outcome and ventricular function in adults with heart failure. Infants with single ventricle physiology
show abnormalities in ventricular function as well as poor growth. The ability of an ACE inhibitor
to preserve ventricular function and improve growth in these infants is unknown.
Methods—The Pediatric Heart Network designed a randomized, double-blind trial to compare
outcomes in infants with single ventricle physiology receiving enalapril or placebo. Neonates ≤ 45
days old were eligible. The primary outcome is weight-for-age Z-score at age 14 months. Secondary
outcomes include other measures of somatic growth, laboratory and functional measures of heart
failure, developmental indices, measures of ventricular size and function and the relationship of the
renin-angiotensin-aldosterone system genotype to the response to enalapril. The incidence and
spectrum of adverse events will also be compared between treatment groups.
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Screening and Enrollment—A total of 1245 neonates were screened and 533 (43%) were
eligible. The consent rate was 43%; 230 subjects were enrolled. Parental reluctance to participate
was the primary reason for non-consent in 79% of the eligible non-consenting patients. Randomized
patients were older, more likely to be male and more likely to have hypoplastic left heart syndrome
than the eligible patients who did not enroll.
Conclusions—The results of this randomized trial will make an important contribution to the
management of infants with single ventricle physiology by determining whether initiation of ACE
inhibition therapy in the neonatal period improves growth, clinical outcome and ventricular function.

Background
Defining the optimal therapeutic approach to the child with single ventricle physiology is one
of the most challenging problems in pediatric cardiology. The benefits of ACE inhibition in
volume-loaded hearts were demonstrated in studies that reported both acute and long-term
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reduction in left ventricular (LV) volume and mass with ACE inhibitor use in children with
chronic valvar regurgitant lesions and other congenital heart defects. 9, 10 In addition, studies
have demonstrated a rapid beneficial effect of ACE inhibition on growth in infants with severe
congestive heart failure,11, 12 with a two-to-threefold increase in weight gain within a oneto-three month follow-up period.13 Although ACE inhibitors are commonly administered to
infants and children for treatment of heart failure due to cardiomyopathy or volume overload
lesions,14 there are few reports regarding administration of ACE inhibitors to infants with
single ventricle physiology15, 16 and no randomized trials evaluating the efficacy of ACE
inhibition in this population have been performed.
Growth impairment is common in infants and children with various forms of congenital heart
disease 1, most often in the presence of congestive heart failure and/or cyanosis. 2 In particular,
growth failure is noted in many infants with single ventricle who manifest both cyanosis and
heart failure.3–5 In infancy and early childhood, the single ventricle is exposed to chronic
hypoxemia and volume overload which can result in an inappropriate increase in myocardial
mass and abnormalities in ventricular systolic and diastolic function. The growth impairment
seen in infants with single ventricle physiology may be the result of persistent or progressive
abnormalities in cardiac structure and function that lead to the development of clinical heart
failure.
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Study Overview
This randomized, double-blind, placebo-controlled trial was designed to determine whether
ACE inhibition improves ventricular function and cardiac output in infants with single ventricle
physiology, thereby decreasing the severity of heart failure in this population.. The primary
hypothesis is that somatic growth will be greater in infants receiving ACE inhibition therapy
compared to those receiving placebo. The primary outcome of weight-for-age Z-score at age
14±1 months was chosen because it is a clinical measure of heart failure that is readily obtained
and easily interpretable. Secondary outcomes include comparison of other measures of somatic
growth, indicators of congestive heart failure, neurodevelopmental indices, echocardiographic
measures of ventricular size and function and the relationship of the renin-angiotensinaldosterone system (RAAS) genotype to response to ACE inhibition. The incidence of adverse
events will also be compared between groups.
This trial was designed by the National Heart, Lung, and Blood Institute (NHLBI)-funded
Pediatric Heart Network (PHN). 17 The study is being conducted at ten clinical centers, three
of which were added 17 months after study initiation to augment the enrollment rate.
(Appendix) A flow chart of the study design is shown in Figure 1.
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Subject Selection
The inclusion and exclusion criteria were chosen to include neonates with stable pulmonary
and systemic blood flow, to minimize the potential negative hemodynamic effects of ACE
inhibition. Patients were excluded based on cardiac anatomy if there was a possibility of a twoventricle repair, e.g., pulmonary atresia with intact ventricular septum. Low birth weight and
non-cardiac conditions associated with poor growth in the first year of life were exclusions
because of the potential confounding effect on the primary outcome of growth. Patients < 35
weeks gestation were excluded because of the possible increased risk of renal dysfunction with
administration of enalapril in this subgroup. The inclusion and exclusion criteria are listed in
Table 1. If the patient met all inclusion and no exclusion criteria, the family was approached
to provide informed consent.
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Subjects were randomly assigned in a 1:1 ratio to the enalapril or placebo treatment groups
using randomly permuted blocks within strata defined by the presence or absence of
hypoplastic left heart syndrome. This stratification was chosen because of the association of
growth impairment with the diagnosis of hypoplastic left heart syndrome. Dynamic balancing
by center was used to ensure that treatment arm totals were balanced within center. All study
personnel, other than the research pharmacist, were masked to the treatment assignment. The
central reader for study echocardiograms was masked to both treatment assignment and study
visit.

Trial Organization
The PHN Infant Single Ventricle Trial Committee and PHN Steering Committee, together with
the NHLBI, are responsible for all aspects of this study. The protocol has been approved by
an independent protocol review committee, a data and safety monitoring board, and by the
institutional review board at each clinical center and at the data coordinating center. The trial
is registered at http://www.clinicaltrials.gov/ct2/show/NCT00113087.

Study Drug
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Enalapril was selected as the ACE inhibitor because it is labeled for use in pediatric patients
with systemic hypertension and is administered twice a day. Pharmacokinetics and dosing data
are available for children as young as 1 month of age. The initial dose was 0.1 mg/kg/day and
was uptitrated as tolerated to the target dose of 0.4 mg/kg/day (Figure 2). At each study visit
the dose of study drug was adjusted for weight gain. Study drug compliance was assessed by
comparing the expected to the measured residual volume of study drug returned to the
pharmacy during the maintenance phase. Study drug was permanently discontinued in the case
of an anaphylactoid reaction, serum creatinine > 1.0 mg/dL, neutropenia (absolute neutrophil
count < 1000 cells/ml) or if open label use of an ACE inhibitor was planned. If study drug was
permanently discontinued the subject was followed until age 14±1 months. A research
investigational new drug application, required due to use of enalapril in neonates without a
previously approved indication, was filed with the United States Food and Drug Administration
prior to initiating the trial.

Outcome Measures
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Study measures were collected at prespecified time points summarized in Figure 1. The
superior cavo-pulmonary anastomosis was electively planned in patients with single ventricle
physiology between 4 and 8 months of age in an attempt to decrease the volume load of the
single ventricle. Patient follow-up until 14 months of age provided at least 6 months of
observation beyond the surgery to assess the effects of ACE inhibition independent of the acute
effects of the superior cavo-pulmonary anastomosis. To determine whether ACE inhibition
therapy improves growth before the superior cavo-pulmonary anastomosis, outcome measures
prior to this procedure were also collected.
Somatic Growth
The primary outcome of weight-for-age Z-score at age 14±1 months of age will be compared
between treatment groups. Height- and head circumference-for-age and weight-for-height will
be compared as secondary outcomes. Training in the accurate and reliable measurement of
weight, height, and head circumference of infants was performed using the training modules
from the Health Resources and Service Administration Maternal and Child Health Bureau
http://depts.washington.edu/growth/. Quality assurance for the primary outcome included a
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third measurement at the exam if the first two measurements were not within 0.1 kg of each
other. Absolute weight, height and head circumference values will be translated into the
corresponding Z-scores for age as determined by the National Health and Nutrition
Examination Survey (http://www.cdc.gov/nccdphp/dnpa/growthcharts/resources/sas.htm).
Severity of Heart Failure
ACE inhibitor therapy may improve ventricular function and thereby reduce signs and
symptoms of heart failure. Therefore, the Ross Heart Failure Score will be used to assess the
effect of ACE inhibition on clinical heart failure,18, 19 and serum B-type natriuretic peptide
(BNP) levels will be used to assess the effect of ACE inhibition on neurohormonal activation.
Ross Heart Failure class and BNP will be assessed prior to the superior cavo-pulmonary
anastomosis and at 14 months of age. Resting BNP levels at these two time points were
measured at a core laboratory using the Shionogi BNP-32 human assay. 20
Neurodevelopmental Status
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The Bayley Scales of Infant Development-Second Edition 21 (BSID-II), MacArthur
Communicative Development Inventory/Words and Gestures (CDI) 22 and the Functional
Status II-Revised (FSII-R) 23 provide a profile of the motor and cognitive capabilities of the
study subjects that will allow assessment of whether ACE inhibition results in improved
functional and neurodevelopmental status relative to placebo at 14 months of age. The BSIDII provides scores designated as the Psychomotor and Mental Development Index scores (PDI
and MDI). Although mild-to-moderate cognitive impairment may be missed by the BSID-II,
the BSID-II has been demonstrated in preliminary studies of infants with single ventricle to be
sensitive in detecting significant neurodevelopment delay.24 The MacArthur CDI is a parentreport instrument for assessing early language skills. The FSII-R is a parent report questionnaire
that measures normal, daily, age-appropriate functions, and has been used to assess the health
status of children with chronic disorders. The instrument correlates well with other markers of
disease. 25 The MacArthur CDI and FSII-R were self-administered in either English or
Spanish.
Ventricular Geometry and Function
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Each subject underwent a complete two-dimensional and Doppler echocardiographic
examination at baseline, prior to the superior cavo-pulmonary anastomosis procedure and at
14 months of age to evaluate ventricular and atrioventricular valve function. Image acquisition
was performed at centers according to a standard technical protocol. Echocardiograms were
interpreted at the Core Echocardiography Laboratory by a single reader to minimize bias and
interobserver error. Measurements to be compared between treatment groups include
ventricular volume, mass, and ejection fraction using a modified biplane Simpson’s algorithm,
vena contracta of regurgitant jets, atrioventricular valve inflow Doppler analysis (peak early
velocity, peak atrial velocity, early deceleration velocity, and a-wave duration), duration of
pulmonary vein flow reversal, tissue Doppler parameters (peak systolic velocity, peak early
and late diastolic velocities), valve gradients, and ventricular flow propagation velocity. 26
Hemodynamic Indices of Cardiac Function
To gain further insight into ventricular function, locally obtained hemodynamic measurements
including the ventricular end diastolic pressure and the pulmonary-to-systemic flow ratio will
be compared between treatment groups in those subjects undergoing cardiac catheterization as
part of routine care before the superior cavo-pulmonary anastomosis.
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Relationship between RAAS Genotype and Response to ACE Inhibition
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RAAS genotype modifies the response of the ventricle to loading conditions 27 and may also
influence the response to therapy. 28 The impact of RAAS polymorphisms on the response to
ACE inhibition will be evaluated by comparing differences in ventricular mass between
treatment groups in subjects with and without RAAS polymorphisms. DNA was extracted from
whole blood in a core laboratory. The following genes will be evaluated: ACE gene,
angiotensinogen gene, angiotensin II receptor type 1 gene, aldosterone synthase gene, and
cardiac chymase A gene. 28, 29
Adverse Events with ACE Inhibition
The incidence and spectrum of adverse events related to ACE inhibition were collected,
including but not limited to hypotension, cyanosis, renal dysfunction, neutropenia, angiodema,
allergic reactions, and rash and will be compared between treatment groups. The impact of
ACE inhibition therapy on the age of the subject at the time of the superior cavo-pulmonary
anastomosis and length of hospital stay will also be evaluated.

Statistical Considerations
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The primary endpoint of the trial is the weight-for-age Z-score determined at age 14±1 months.
Existing data from the literature 3, 4 and Columbia University indicated that the standard
deviation of weight-for-age Z-scores in this patient population is approximately 1.1. A mean
difference between treatment groups of half a standard deviation (mean Z-score difference of
0.5) was considered clinically meaningful. At age 14 months this is equivalent to a 0.52 kg
mean difference between treatment groups. The mean weight-for-age Z-score of subjects in
the placebo group at age 14 months is expected to be about the 10th percentile for age. A mean
group difference in Z-scores of 0.5 results in a mean Z-score equivalent to the 22.5th weight
percentile for age in the ACE inhibition group. A total of 176 subjects (88 per arm) is required
to detect this difference with 85% power using a two-sided .05 level test. Using a conservative
inflation rate (20% for loss to follow-up and 3% for group sequential interim analysis), a total
target of 230 subjects were randomized (115 per arm).
Interim Analysis
One formal interim analysis was planned and executed when approximately half the subjects
reached the 14±1 month visit. Lan-DeMets methodology was used to adjust the boundary
appropriately for the precise timing of the interim analysis. 30
Analysis Plan
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The primary analysis will be according to the intention-to-treat principle. All subjects will be
analyzed according to their treatment group assignment regardless of actual treatment received.
The mean weight-for-age Z-score at age 14±1 months of the two groups will be compared
using the t-test. If there is a severe departure from normality, the Wilcoxon rank sum test will
be conducted because the presence of negative Z-scores prevents simple transformation of the
data. The mean of the two closest measurements made at the exam is used as the final value
for analysis. If a subject is withdrawn from the trial, imputation of weight at 14 months will
not be conducted, because it is not known what effect the superior cavo-pulmonary anastomosis
may have on weight. Longitudinal weight measurements will be analyzed using mixed model
analysis of variance to determine the association over time between ACE inhibitor use and
growth.
If there are imbalances on covariates that are prognostic for study outcomes, then covariateadjusted comparisons will be made as a secondary analysis. A secondary non-intent-to-treat
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analysis will also be performed using a categorical measure of compliance to account for
treatment crossover.
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Subgroup Analyses
Covariate by treatment group interaction tests will be performed to test whether the treatment
effect is homogenous across subgroups. Statistical testing within subgroups will not be
conducted unless the interaction test p-value is <0.10. Prespecified subgroups are:
• Genotype: The presence or absence of RAAS gene polymorphisms
•

Heterotaxy versus no heterotaxy

•

Type of systemic single ventricle: Left ventricle versus non-left ventricle

•

Type of initial surgical palliation: Norwood versus other palliation

•
•

Type of surgery performed to control pulmonary blood flow in the Norwood
procedure: Right ventricular to pulmonary artery conduit vs. aortopulmonary shunt
The presence or absence of recurrent coarctation requiring intervention

Time-Line and Trial Enrollment
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The enrollment period was from August, 2003 through July 2007, and the last subject is
expected to complete the end-of-study visit in September, 2008. Of the 1245 patients screened
during the enrollment period, 712 (57%) did not meet eligibility criteria. Figure 3 summarizes
the reasons for exclusion. Inalterable exclusions were present in 450 (63%) of 712 patients.
Treatment with open label ACE inhibition during the screening period was the reason for
exclusion in 61/712 (9%) ineligible patients. Other reasons for non-eligibility included distance
from center and the presence of hemodynamic instability requiring mechanical ventilation or
inotropic support. Consent was not obtained in 303 (57%) of the 533 eligible patients. Parental
or guardian reluctance to participate in the study was the primary reason for non-consent in
79%. Consent was not sought in 7% because of planned open label use of ACE inhibition.
Table 2 summarizes the characteristics of the screened population and compares demographics
of the eligible patients who did and did not provided consent for randomization. There were
several significant differences among the enrolled and not enrolled eligible patients. Patients
who were enrolled were more likely to be older at screening completion, to be male and to
have hypoplastic left heart syndrome by univariate analysis. The enrolled and not enrolled
eligible patients were similar in regard to gestational age, birth weight, race, and type and
number of surgeries prior to enrollment.
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Conclusions
This trial is designed to assess the safety and efficacy of ACE inhibition in infants with single
ventricle physiology during the first year of life and represents the first double-blind,
randomized, placebo controlled trial of medical therapy to be performed in this population.
The primary outcome of weight-for-age Z-score was chosen because growth impairment is
common in these infants and ventricular performance is an important factor influencing growth.
Secondary outcomes were chosen to assess the impact of ACE inhibition on ventricular
remodeling and clinical outcomes, such as heart failure symptoms and neurodevelopment. This
study will provide data to determine if RAAS polymorphisms have an important role in
modulating the effect of ACE inhibition in this population. By standardizing the drug
administration protocol and collecting adverse events prospectively, the data will allow
informed risk/benefit assessment of the use of ACE inhibition in this medically fragile
population.
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Patients who underwent surgical intervention were not eligible for trial enrollment for the first
three post-operative days and until such time that stable systemic and pulmonary blood flow
was established. Several discussions with the family were often needed to explain the study
procedures and obtain consent. Hospital stay and thus access to the parents or guardian for
study recruitment were shorter for patients not having surgery and for those undergoing simpler
procedures, such as aorto-pulmonary shunt or pulmonary artery banding, than for patients
undergoing the Norwood procedure. Differences between the non-randomized and randomized
trial-eligible population are explained in part by the fact that patients with hypoplastic left heart
syndrome were in the hospital for a longer period of time, allowing the study investigators and
nurse coordinators greater access to the family during the recruitment process.
The 1245 neonates screened and 230 subjects enrolled in this study are by far the largest number
of subjects screened and enrolled in a medical treatment trial in infants with single ventricle
physiology. The results of this double-blind randomized placebo controlled trial will allow the
formulation of evidence-based recommendations regarding the use the ACE inhibition in the
first year of life in infants with single ventricle physiology.
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Figure 1. Pediatric Heart Network Infant Single Ventricle Trial Protocol

SCPA=superior cavo-pulmonary anastomosis, HF = heart failure, BNP = B-type natriuretic
peptide, Echo = echocardiogram
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Figure 2.

Preparation and Uptitration of Study Drug
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Figure 3. Pediatric Heart Network Infant Single Ventricle Trial Screening Results

IV= intravenous, abs= absolute
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Table 1

Inclusion and Exclusion Criteria
Inclusion Criteria
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1

Age ≤ 45 days

2

Age > 1 week if born at 35 weeks gestation

3

Single ventricle physiology

4

Stable systemic and pulmonary blood flow

5

Planned superior cavo-pulmonary anastomosis (either the bi-directional Glenn shunt or hemi-Fontan surgery)

Exclusion Criteria

NIH-PA Author Manuscript

1

Birth weight ≤ 2.5 kg if gestational age is ≥ 38 weeks; birth weight < the 5th percentile for gestational age if gestational age is 35–37 weeks

2

< 35 weeks gestation

3

Anatomic diagnosis of pulmonary atresia with intact ventricular septum

4

< 3 days after palliative cardiac surgical procedure, if performed

5

Systemic oxygen saturation < 65%

6

Current mechanical ventilatory support

7

Current intravenous inotropic support

8

Creatinine >1.0 mg/dL

9

Absolute neutrophil count <1000 cells/mL

10

Chromosomal or recognizable phenotypic syndrome of non-cardiac congenital abnormalities associated with growth failure (e.g. trisomy
21, Noonan syndrome, Turner syndrome)

11

Prior ACE inhibitor use for > 7 consecutive days

12

Unable to return for follow-up because of distance from clinical site.
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Table 2

Infant Single Ventricle Trial Baseline Characteristics by Screening Status
Eligible

NIH-PA Author Manuscript

Characteristic

Ineligible

N

Not Enrolled

Enrolled

P-value*

712

303

230

11.9 ± 11.1

11.3 ± 8.4

13.8 ± 9.2

<.001

Male

11.8 ± 11.3

11.3 ± 7.5

13.2 ± 8.0

0.028

Female

12.0 ± 10.9

11.2 ± 9.7

15.4 ± 11.4

0.008

Mean Age at Screening, Days

Median (Q1,Q3) Age at Screening, Days

8.0 (4.0, 15.5)

10.0 (5.0, 14.0)

13.0 (8.0, 17.0)

<.001

Male

8.0 (4.0, 15.0)

10.0 (6.0, 14.5)

13.0 (8.0, 16.0)

0.008

Female

9.0 (4.0, 16.0)

9.0 (4.0, 14.0)

12.5 (6.5, 22.0)

0.010

58%

61%

70%

0.022

White

74%

72%

80%

Black or African American

18%

18%

14%

Asian

4%

4%

3%

Male
Race

0.096

NIH-PA Author Manuscript

Other

4%

6%

3%

Hispanic

18%

14%

15%

0.703

Gestational Age <37 weeks

22%

9%

9%

0.879

38.0 (37.0, 39.0)

39.0 (38.0, 40.0)

38.0 (37.0, 39.0)

0.212

2.9 ± 0.7

3.2 ± 0.5

3.3 ± 0.5

0.283

Male

3.0 ± 0.7

3.3 ± 0.5

3.3 ± 0.5

0.383

Female

2.8 ± 0.7

3.2 ± 0.4

3.2 ± 0.5

0.948

Single Ventricle

33%

36%

29%

Hypoplastic Left Heart

42%

54%

63%

Other Functional SV

23%

9%

8%

Median (Q1,Q3) Gestational Age,
Weeks**
Mean Birth Weight, kg

Single Ventricle Anatomic Diagnosis

Unclassified

0.168

2%

0.3%

0.4%

53%

50%

46%

Norwood

48%

66%

72%

Systemic-to-Pulmonary Shunt

25%

21%

17%

Pulmonary artery Band

6%

7%

6%

Damus-Kaye-Stansel

1%

1%

3%

Other

20%

5%

2%

Median number of concurrent surgeries

0.0 (0.0, 1.0)

0.0 (0.0, 1.0)

0.0 (0.0, 1.0)

0.317

Median number of interventional
cardiac catheterizations: birth to
screening

0.0 (0.0, 0.0)

0.0 (0.0, 0.0)

0.0 (0.0, 0.0)

0.116

Median number of other cardiac
surgeries: post-palliation to screening

0.0 (0.0, 1.0)

0.0 (0.0, 1.0)

1.0 (0.0, 1.0)

0.061

At least 1 Associated Anatomic
Diagnosis
Type of Surgery

0.370
0.138
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*

Test of significance for differences between enrolled patients and eligible but not enrolled patients. Exact test for categorical variables and t-test or
Wilcoxon rank sum test for continuous variables
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**

Gestational age imputed as 40 weeks for 72 full-term patients.
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